Ovid Therapeutics Inc. (OVID) - Latest Market Data

Price & Market Data

Price: $2.48

Daily Change: +$0.04 / 1.61%

Daily Range: $2.43 - $2.53

Market Cap: $461,001,056

Daily Volume: 1,339,244

Performance Metrics

1 Week: -11.41%

1 Month: -13.41%

3 Months: 64.57%

6 Months: 100.4%

1 Year: 728.3%

YTD: 50.61%

About Ovid Therapeutics Inc. (OVID)

Uncover the latest on Ovid Therapeutics Inc. (OVID). Trading at 2.48, the stock has shown a daily change of +$0.04 / 1.61%. With a market cap of 461,001,056, its performance over the last week (-11.41%) and month (-13.41%) provides key insights.

Company Details

Employees: 23

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Selected stocks

Generation Income Properties Inc. (GIPR)

ICZOOM Group Inc. (IZM)

Redhill Biopharma Ltd. (RDHL)

Biodexa Pharmaceuticals plc (BDRX)

Rapid Micro Biosystems, Inc. (RPID)